ID: ALA2408617

Max Phase: Preclinical

Molecular Formula: C18H13N5OS

Molecular Weight: 347.40

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cn1cc(-c2cnc(N)c3oc(-c4csc5cnccc45)cc23)cn1

Standard InChI:  InChI=1S/C18H13N5OS/c1-23-8-10(5-22-23)13-6-21-18(19)17-12(13)4-15(24-17)14-9-25-16-7-20-3-2-11(14)16/h2-9H,1H3,(H2,19,21)

Standard InChI Key:  UPJJRELFFCGJGA-UHFFFAOYSA-N

Associated Targets(Human)

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine/threonine-protein kinase Aurora-B 6805 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mitogen-activated protein kinase kinase kinase 7 1167 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

TAK1/TAB1 257 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 347.40Molecular Weight (Monoisotopic): 347.0841AlogP: 4.09#Rotatable Bonds: 2
Polar Surface Area: 82.76Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.46CX LogP: 1.98CX LogD: 1.98
Aromatic Rings: 5Heavy Atoms: 25QED Weighted: 0.52Np Likeness Score: -1.03

References

1. Hornberger KR, Chen X, Crew AP, Kleinberg A, Ma L, Mulvihill MJ, Wang J, Wilde VL, Albertella M, Bittner M, Cooke A, Kadhim S, Kahler J, Maresca P, May E, Meyn P, Romashko D, Tokar B, Turton R..  (2013)  Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.,  23  (16): [PMID:23856049] [10.1016/j.bmcl.2013.06.054]

Source